Immunotherapy and radiation for esophageal cancer that didn't respond to initial treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (toripalimab), chemotherapy, and low-dose radiation for people with esophageal cancer that did not shrink after initial chemotherapy and immunotherapy. The goal is to see if this new combination can help control the cancer before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older with a type of esophageal cancer called squamous cell carcinoma.
- You must have completed at least 2 rounds of chemotherapy plus immunotherapy before joining, and your cancer must have stayed stable (not grown) after that treatment.
- You must be in good general health, with a performance status score of 0 or 1 (meaning you can do most daily activities).
- Your blood tests must meet certain levels for white blood cells, platelets, hemoglobin, and kidney and liver function.
- You must be willing to provide tumor tissue and blood samples for research.
- If you are of childbearing age, you must agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether continuing a type of immunotherapy (toripalimab) after standard chemoradiation helps keep advanced esophageal cancer from growing, compared to just watching and waiting. If you've already completed initial treatment without the cancer getting worse, this study might help you stay stable longer.
This trial tests a new combination of immunotherapy (toripalimab) with two chemotherapy drugs before surgery for esophageal cancer, compared to a standard chemo regimen. The goal is to see if the new combination improves outcomes for patients with resectable tumors.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
This trial tests a treatment approach that combines low-dose radiation with immunotherapy and chemotherapy for people with esophageal cancer that is hard to remove with surgery. The goal is to shrink the tumor enough to make surgery possible, which could improve outcomes.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.